ADMA Biologics, Inc. Form 4 Filings

ADMA Biologics CFO and Treasurer Terry Kohler received equity awards on July 16, 2026. He was granted 85,130 restricted stock units (RSUs) that vest over four years, bringing his unvested RSUs to 143,149, including 58,019 from a December 8, 2025 grant. He also received a stock option for 136,363 shares of common stock at an exercise price of $8.81 per share, vesting 25% after one year and the remainder in substantially equal monthly installments through July 16, 2030, with an expiration date of July 16, 2036.

ADMA Biologics director Jerrold B. Grossman reported buying 6,400 shares of common stock at $7.91 per share in an open-market transaction on May 27, 2026. Following this purchase, his directly held position, including 10,690 restricted stock units and 509,594 common shares, totaled 520,284 shares.

He also reported indirect holdings of ADMA common stock through several related entities and relationships: 175 shares held by Brookwood LLC, 38,294 shares held by the Jerrold Grossman 2019 Irrevocable Trust, 31,381 shares held by Genesis Foundation Inc., and 22,857 shares held by his wife.

ADMA Biologics director Jerrold B. Grossman bought additional shares of company stock. On May 12, 2026, he made an open-market purchase of 12,500 shares of ADMA common stock at $8.01 per share. Following this transaction, he directly holds 513,884 common shares, which includes 10,690 RSUs granted on February 9, 2026 that vest in two equal installments on August 9, 2026 and February 9, 2027, along with 503,194 owned shares. He also has several indirect holdings: 175 shares through Brookwood LLC, 38,294 shares through the Jerrold Grossman 2019 Irrevocable Trust, 31,381 shares held by Genesis Foundation Inc., and 22,857 shares owned by his wife.

ADMA Biologics director Jerrold B. Grossman bought 12,500 shares of common stock in an open-market transaction at $8.01 per share. Following this purchase, his directly owned stake shown in the filing increased to 501,384 shares of ADMA common stock.

The filing also lists additional ADMA shares held indirectly through Brookwood LLC, the Jerrold Grossman 2019 Irrevocable Trust, Genesis Foundation Inc., and his wife, reflecting interests associated with the director beyond his direct holdings.

ADMA Biologics COO and SVP, Compliance Kaitlin M. Kestenberg-Messina had 20,362 shares of common stock withheld at $9.11 per share to cover taxes on vesting restricted stock units. These shares were retained by the company to satisfy mandatory tax withholding and were not sold in the open market.

After this tax-withholding disposition, she directly holds 446,238 shares of ADMA common stock. Footnotes indicate this total includes multiple blocks of unvested restricted stock units that vest in quarterly installments over four years and common shares from prior option exercises and net share settlements.

ADMA Biologics director Lawrence P. Guiheen reported a mix of option exercises and charitable estate planning transactions. On March 13, 2026, he exercised stock options to acquire 30,000 shares of common stock at $3.66 per share, increasing his direct equity stake. On March 17, 2026, he made bona fide gifts totaling 60,000 shares of common stock, including 30,000 shares transferred directly and 30,000 shares gifted to the 2019 Guiheen Irrevocable Trust, over which he retains control but disclaims beneficial ownership except for any pecuniary interest. After these transactions, he holds 105,520 shares directly, with additional shares held indirectly through irrevocable trusts as described in the footnotes.

ADMA Biologics President and CEO Adam S. Grossman exercised stock options for 15,000 shares of common stock at $5.40 per share on March 16, 2026, then sold 21,000 shares of common stock at $15.16 per share in open-market transactions.

The filing shows these trades were effected under a Rule 10b5-1 trading plan entered into on November 14, 2025. After the transactions, Grossman holds 2,112,777 shares of ADMA Biologics common stock directly, while entities Areth, LLC and Hariden, LLC hold 1,143,426 and 580,957 shares indirectly associated with him.

ADMA Biologics COO and SVP, Compliance Kaitlin M. Kestenberg-Messina reported multiple stock transactions. She exercised stock options to acquire 10,096 shares of common stock at exercise prices ranging from $1.55 to $5.00 per share. In connection with restricted stock unit vesting, 14,294 shares were withheld to cover mandatory tax obligations, which did not involve open-market sales. She also transferred 91,266 shares and sold 10,096 shares of common stock at a weighted average price of $15.63 per share, both carried out under a court-approved divorce settlement. Following these transactions, she directly owned 466,600 shares of ADMA Biologics common stock.

ADMA Biologics President and CEO Adam S. Grossman reported tax-related share withholdings rather than market trades. On March 6–7, 2026, a total of 85,951 shares of Common Stock were withheld at $15.39 per share to satisfy mandatory tax obligations upon vesting of restricted stock units, as noted in the footnotes. After these withholdings, he directly held 2,118,777 shares of Common Stock. Separate holding entries show additional indirect ownership of 1,143,426 shares through Areth, LLC and 580,957 shares through Hariden, LLC, entities over which he has control roles.

ADMA Biologics director-affiliated funds reported open-market purchases of common stock. Entities associated with director Steve Elms bought a total of 14,000 ADMA shares, with 7,000 shares purchased on March 5, 2026 at a weighted average price of $15.67 per share and 7,000 shares on March 6, 2026 at a weighted average price of $15.39 per share.

The filing notes these shares are held by Aisling Capital II LP and Aisling Arcturus Partners, LP, and that Mr. Elms may be deemed a beneficial owner through his roles at Aisling entities while disclaiming beneficial ownership except to the extent of his pecuniary interest. Following these transactions, Aisling-related entities reported 2,045,730 shares, while Mr. Elms also directly holds 87,330 shares and 10,690 restricted stock units that are scheduled to fully vest on February 9, 2027, subject to continued service.

ADMA Biologics President and CEO Adam S. Grossman reported a tax-related share disposition tied to restricted stock unit vesting. On the transaction date, 54,858 shares of common stock were withheld at $15.18 per share to satisfy mandatory tax withholding obligations, and this was explicitly noted as not an open market sale.

After this withholding, Grossman directly owned 2,204,728 shares of ADMA common stock. He also had indirect ownership of 1,143,426 shares through Areth, LLC and 580,957 shares through Hariden, LLC, entities for which he is disclosed as a control person or managing member.

ADMA Biologics, Inc. executive Kaitlin M. Kestenberg-Messina, COO and SVP, Compliance, reported a Form 4 transaction involving company common stock. On February 19, 2026, 8,161 shares were withheld by the company at $16.32 per share to cover mandatory tax withholding on vesting restricted stock units, which is not an open market sale. After this tax-withholding disposition, she directly held 572,160 shares of common stock, reflecting prior option exercises and earlier RSU net settlements.

ADMA Biologics CFO and Treasurer Brad L. Tade reported a tax-related share disposition tied to restricted stock units (RSUs). On the transaction date, 6,479 shares of common stock were withheld by the company at $16.32 per share to satisfy mandatory tax withholding when RSUs vested, and this was not an open market sale. After this withholding, Tade directly owned 232,940 shares of common stock, including multiple blocks of unvested RSUs granted between June 2023 and February 2025 that will settle into shares over time if service conditions are met.

ADMA Biologics President and CEO Adam S. Grossman reported a Form 4 transaction where 24,793 shares of common stock were withheld on February 19, 2026 at $16.32 per share to cover mandatory tax obligations upon the vesting of restricted stock units. Footnotes clarify this was a tax-withholding disposition and not an open market sale.

After this transaction, Grossman directly owned 2,259,586 shares of ADMA common stock. He also had indirect ownership of additional shares, including positions held through Areth, LLC and Hariden, LLC, where he is a control person and managing member, respectively.

ADMA Biologics President and CEO Adam S. Grossman reported a mix of option exercise and share sales. On February 17, 2026, he exercised a stock option for 15,000 shares at $5.40 per share, converting it into 15,000 shares of common stock. He then sold a total of 21,000 common shares in open-market transactions at $16.08 per share under a Rule 10b5-1 trading plan.

After these transactions, he directly holds 2,284,379 common shares. He also has indirect holdings of 1,143,426 shares through Areth, LLC and 580,957 shares through Hariden, LLC. Footnotes note multiple unvested RSU awards granted between 2022 and 2026 that vest over four years and settle in common stock, plus previously acquired shares reflecting prior RSU vesting and purchases.

ADMA Biologics director Jerrold B. Grossman received new equity awards. On February 9, 2026, he was granted 10,690 restricted stock units of common stock at $0, which vest in two equal installments over one year, subject to continued service.

He was also granted stock options for 17,730 shares of common stock at a $16.37 exercise price, with these options vesting in twelve equal monthly installments over one year. Following the grant, he directly beneficially owned 488,884 shares of common stock, including previously granted RSUs, and held additional indirect interests through an LLC, a trust, a foundation, and his spouse.

ADMA Biologics COO and SVP, Compliance Kaitlin M. Kestenberg-Messina reported new equity awards. On February 9, 2026, she received 91,631 shares of common stock as restricted stock units at $0 per share and a stock option for 144,230 shares with a $16.37 exercise price.

The RSUs vest quarterly on each annual anniversary of the grant date over four years under the 2022 Equity Compensation Plan, subject to continued service. The option vests over four years, with 25% vesting on the one-year anniversary and the remaining 75% vesting monthly until becoming fully vested on February 9, 2030. Following these grants, she beneficially owns 580,321 shares of common stock and 144,230 stock options, all held directly.

ADMA Biologics President and CEO Adam S. Grossman reported new equity awards. On February 9, 2026, he acquired 282,529 shares of common stock in the form of restricted stock units granted at $0 and 444,711 stock options with a $16.37 exercise price.

The RSUs vest quarterly over four years under ADMA’s 2022 Equity Compensation Plan, subject to his continued service. The options also vest over four years, with 25% vesting on the one‑year anniversary and the remaining 75% vesting monthly until fully vested on February 9, 2030. After these awards, he directly beneficially owns 2,290,379 shares of common stock and also has indirect ownership of additional ADMA shares through Areth, LLC and Hariden, LLC.

ADMA Biologics director Young Kwon reported new equity awards. On February 9, 2026, he received 10,690 shares of common stock in the form of restricted stock units granted at $0, which vest in two equal installments over one year, subject to continued service. He also received a stock option to buy 17,730 shares of common stock at an exercise price of $16.37 per share, vesting in twelve equal monthly installments and becoming fully vested on February 9, 2027. After these awards, he directly holds 263,020 shares of common stock, including RSUs, and 17,730 stock options.

ADMA Biologics director Alison C. Finger received new equity awards in the form of restricted stock units (RSUs) and stock options on February 9, 2026. She acquired 10,690 RSUs at a price of $0, bringing her directly held common stock and RSU-related holdings to 45,619 shares.

The 10,690 RSUs vest in two equal installments on the six- and 12‑month anniversaries of the grant date, becoming fully vested after one year, subject to continued service. She was also granted stock options for 17,730 shares of common stock at an exercise price of $16.37, which vest in twelve equal monthly installments over one year.

ADMA Biologics director Eduardo Rene Salas reported new equity awards. On February 9, 2026, he acquired 10,690 shares of common stock in the form of restricted stock units, granted at a price of $0, which will vest in two equal installments over one year.

Following this grant, he beneficially owned 21,579 shares of common stock, including previously granted RSUs and 5,444 owned shares. He was also granted stock options to buy 17,730 shares of common stock at an exercise price of $16.37, vesting in twelve equal monthly installments and becoming fully vested one year from the grant date.

ADMA Biologics director Lawrence P. Guiheen reported new equity awards and updated his holdings. On February 9, 2026, he received 10,690 restricted stock units at $0 and a stock option for 17,730 shares at an exercise price of $16.37.

The RSUs vest in two equal installments on the six- and 12‑month anniversaries of the grant date, becoming fully vested on February 9, 2027, subject to continued service. The options vest in twelve equal monthly installments over one year. After these grants, he directly beneficially owns 105,520 shares of common stock and indirectly holds 50,990 shares through the Lawrence P Guiheen Irrevocable Trust 1.

ADMA Biologics director Steve Elms reported new equity awards. On February 9, 2026, he acquired 10,690 restricted stock units of common stock at $0 and a stock option to buy 17,730 shares at $16.37, also valued at $0 on grant.

After these awards, he directly holds 98,020 shares of common stock (including RSUs) and 17,730 stock options. The filing also notes 2,031,730 shares of common stock held indirectly through Aisling Capital II LP, where he may be deemed a beneficial owner but disclaims beneficial ownership except for his pecuniary interest.

ADMA Biologics’ president and CEO reported option exercises and stock sales in company shares. On 12/15/2025, he exercised a stock option covering 15,000 shares of common stock at an exercise price of $5.40 per share and, on the same date, sold 15,000 shares and a separate 6,000-share block at a sale price of $19.79 per share. The transactions were carried out under a Rule 10b5-1 trading plan entered into on December 5, 2024 with Fidelity Brokerage Services LLC. Following these trades, he directly holds 2,007,850 shares of ADMA Biologics common stock, along with indirect holdings of 1,143,426 shares through Areth, LLC and 580,957 shares through Hariden, LLC, and continues to hold 720,950 stock options.

ADMA Biologics (ADMA) reported insider equity activity by its President, CEO and Director, Adam S. Grossman. On 11/19/2025, he exercised a stock option to acquire 15,000 shares of common stock at an exercise price of $5.40 per share, then sold 15,000 shares and an additional 6,000 shares of common stock at a sale price of $16.00 per share. The transactions were carried out under a pre-arranged Rule 10b5-1 trading plan entered into on December 5, 2024. Following these transactions, he directly owned 2,013,850 shares of common stock, with additional indirect ownership of 1,143,426 shares through Areth, LLC and 580,957 shares through Hariden, LLC, along with 735,950 stock options and multiple tranches of unvested RSUs that vest over four-year schedules.

ADMA Biologics (ADMA) President & CEO and Director Adam S. Grossman reported Form 4 transactions on 10/24/2025. He exercised 15,000 stock options at $5.40 (Code M) and sold 15,000 and 6,000 common shares at $16 (Code S) under a Rule 10b5-1 trading plan.

After these trades, he held 2,019,850 shares directly. He also reported indirect holdings of 1,143,426 shares via Areth, LLC and 580,957 shares via Hariden, LLC, as disclosed in the footnotes.